CoChat

Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy

Open access
Iribarren, Kristina, Bloy, Norma, Buqué, Aitziber, Cremer, Isabelle, Eggermont, Alexander, Fridman, Wolf Hervé, Fucikova, Jitka, Galon, Jérôme, Špíšek, Radek, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo · 2016 · OncoImmunology
Cited by 131

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Accumulating preclinical evidence indicates that Toll-like receptor (TLR) agonists efficiently boost tumor-targeting immune responses (re)initiated by most, if not all, paradigms of anticancer immunotherapy. Moreover, TLR agonists have been successfully employed to ameliorate the efficacy of various chemotherapeutics and targeted anticancer agents, at least in rodent tumor models. So far, only three TLR agonists have been approved by regulatory agencies for use in cancer patients. Moreover, over the past decade, the interest of scientists and clinicians in these immunostimulatory agents has been fluctuating. Here, we summarize recent advances in the preclinical and clinical development of TLR agonists for cancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2015.1088631

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 131

Metadata

Authors
Iribarren, K., Bloy, N., Buqué, A., Cremer, I., Eggermont, A., Fridman, W. H., Fucikova, J., Galon, J., Špíšek, R., Zitvogel, L., Kroemer, G., & Galluzzi, L.
Venue
OncoImmunology
Published
2015-09-02
Volume
5
Issue
3
Pages
e1088631
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2256675122
Cited by
131
References
24
FWCI
6.32
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. https://app.cochat.ai/papers/10.1080/2162402x.2015.1088631
The paper
Iribarren, K., Bloy, N., Buqué, A., Cremer, I., Eggermont, A., Fridman, W. H., Fucikova, J., Galon, J., Špíšek, R., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2016). Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. OncoImmunology. https://doi.org/10.1080/2162402x.2015.1088631

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.